UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Unicycive Therapeutics, Inc. for violations of the Securities Exchange Act of 1934 [1][4] - The class period for the lawsuit is defined as between March 29, 2024, and June 27, 2025, during which investors are encouraged to participate if they suffered losses [2] - The complaint alleges that Unicycive made false and misleading statements regarding its FDA manufacturing compliance and the likelihood of FDA approval for its treatment OLC [4] Group 2 - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3] - The class has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation [5]